NEW YORK (AP) — Drug developer Forest Laboratories Inc. said Friday its developing antibiotic ceftaroline met key study goals in treating hospital-acquired pneumonia. In two late-stage, or Phase III clinical trials, the drug had a higher cure rate than the antibiotic ceftriaxone in patients with moderate to severe forms of the condition. The company expects to ask for FDA approval near the end of the year.
Related Articles Read More >
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
Eicos Sciences’ FDA-approved Aurlumyn promises to drastically reduce frostbite amputations
